scPharmaceuticals Inc
NASDAQ:SCPH

Watchlist Manager
scPharmaceuticals Inc Logo
scPharmaceuticals Inc
NASDAQ:SCPH
Watchlist
Price: 5.67 USD Market Closed
Market Cap: $304.4m

Net Margin

-183.5%
Current
Improving
by 388.3%
vs 3-y average of -571.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-183.5%
=
Net Income
$-91.7m
/
Revenue
$50m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-183.5%
=
Net Income
$-91.7m
/
Revenue
$50m

Peer Comparison

Country Company Market Cap Net
Margin
US
scPharmaceuticals Inc
NASDAQ:SCPH
302.2m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Lower than 87% of companies in the United States of America
Percentile
13th
Based on 15 072 companies
13th percentile
-183.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

scPharmaceuticals Inc
Glance View

Market Cap
304.4m USD
Industry
Pharmaceuticals

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.

SCPH Intrinsic Value
7.4 USD
Undervaluation 23%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-183.5%
=
Net Income
$-91.7m
/
Revenue
$50m
What is scPharmaceuticals Inc's current Net Margin?

The current Net Margin for scPharmaceuticals Inc is -183.5%, which is above its 3-year median of -571.8%.

How has Net Margin changed over time?

Over the last 2 years, scPharmaceuticals Inc’s Net Margin has increased from -1 957.3% to -183.5%. During this period, it reached a low of -1 957.3% on Mar 31, 2023 and a high of -183.5% on Jul 30, 2025.

Back to Top